This licence represents another major milestone for Arobella Medical’s passionate pursuit to advance the standard of care when it comes to treating and healing wounds.

Eliaz Babaev, CEO and President of Arobella Medical, LLC, “Currently in negotiations with several distributors, we are trying to bring this technology all across Canada and all the various provinces.”

He added, “We are glad we can finally bring this improved standard of care to current wound care practices and facilities and offer another tool to improve the quality of life for patients with a wide variety of chronic and other types of troublesome wounds.”

The Qoustic Wound Therapy System™, Model AR1000 Series and its variants had previously received, under FDA 510(k) clearance (K131096), new and expanded claims and indications for use, as indicated below:

The Qoustic Wound Therapy System™ is indicated for producing and delivering low frequency ultrasound used to promote wound healing via:

Surgical, excisional or sharp-edge wound debridement (acute and chronic wounds, burns) for the removal of nonviable tissue including but not limited to diseased tissue, necrotic tissue, slough and eschar, fibrin, tissue exudates, bacteria and other matter